Business Standard

Natco Pharma profit before tax drops 40% in Q2 to Rs 139 cr on tepid sales

The board of directors of Natco Pharma has recommended second interim dividend of Rs 1 per equity share of Rs 2 each

company results, Q2, second quarter
Premium

Illustration by Ajay Mohanty

BS Reporter
Natco Pharma Limited has reported a 40 per cent decline in consolidated profit before tax to Rs 139.4 crore for the quarter ended September, 2019, compared with Rs 235.3 crore in the corresponding quarter last year.

Total income for quarter under review also declined 11 per cent to Rs 518.9 crore from Rs 583.5 crore in the year ago period. The company said the decline in revenues and profits compared to the same period last year was primarily due to the anticipated drop in oseltamivir product sales in the US and Hep C sales in India.

The board of directors

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in